Geron (GERN) EV to CFO (2010 - 2026)
Geron's (GERN) quarterly EV to CFO came in at 32.95 in Q2 2026, down 76.57% year-over-year from 140.61 in Q2 2025, and down 223.38% quarter-over-quarter from 10.19 in Q1 2026.
Powered by 
Analysis
Geron (GERN) EV to CFO (2010 - 2026) Analysis & Trends
Geron has disclosed EV to CFO across 17 years of filings, most recently posting 32.95 for Q2 2026.
- In Q2 2026, EV to CFO fell 76.57% year-over-year to 32.95; the TTM figure through Jun 2026 stood at 4.56 (down 58.89% YoY), while the FY2025 annual figure was 4.38, up 44.93% from the prior year.
- EV to CFO came in at 32.95 for Q2 2026 at Geron, down from 10.19 in the prior quarter.
- In the past five years, EV to CFO ranged from a high of 10.19 in Q1 2026 to a low of 44.21 in Q2 2023.
- Average EV to CFO over 5 years is 24.64, with a median of 21.99 recorded in 2022.
- Year-over-year, EV to CFO plunged 245.65% in 2023 and soared 54.49% in 2025.
- Over 5 years, EV to CFO stood at 21.93 in 2022, then climbed by 9.12% to 19.93 in 2023, then slumped by 98.63% to 39.6 in 2024, then soared by 44.3% to 22.06 in 2025, then sank by 49.4% to 32.95 in 2026.
- Per Business Quant data, the three most recent EV to CFO figures were 32.95 in Q2 2026, 10.19 in Q1 2026, and 22.06 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.95 |
| Mar 31, 2026 | -10.19 |
| Dec 31, 2025 | -22.06 |
| Sep 30, 2025 | -36.39 |
| Jun 30, 2025 | -18.66 |
| Mar 31, 2025 | -12.84 |
| Dec 31, 2024 | -39.60 |
| Sep 30, 2024 | -40.80 |
| Jun 30, 2024 | -41.01 |
| Mar 31, 2024 | -24.32 |
| Dec 31, 2023 | -19.93 |
| Sep 30, 2023 | -16.48 |
| Jun 30, 2023 | -44.21 |
| Mar 31, 2023 | -15.60 |
| Dec 31, 2022 | -21.93 |
| Sep 30, 2022 | -23.57 |
| Jun 30, 2022 | -12.79 |
| Mar 31, 2022 | -10.20 |
| Dec 31, 2021 | -9.53 |
| Sep 30, 2021 | -11.60 |